Advertisement
Advertisement
PTN
Palatin Technologies, Inc. Common Stock
6.89
USDSponsored
-0.34
-4.70%
Nov 10, 15:58 UTC -5
Closed
After-Market
6.98
+0.09
+1.29%
Palatin Technologies, Inc. Common Stock (PTN) Earnings
PTN Earnings Reports
Positive Surprise Ratio
PTN beat 20 of 39 last estimates.
51%
Next Report
Tomorrow
Date of Next Report
Nov 11, 2026
Estimate for Q1 27 (Revenue/ EPS)
$2.54M
/-$0.42
Implied change from Q4 26 (Revenue/ EPS)
+743.06%
/-62.16%
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Palatin Technologies, Inc. Common Stock earnings per share and revenue
On Sep 28, 2026, PTN reported earnings of -1.11 USD per share (EPS) for Q4 26, beating the estimate of -1.21 USD, resulting in a 8.42% surprise. Revenue reached 301.00 thousand, compared to an expected 1.26 million, with a -76.16% difference. The market reacted with a +0.49% price change (close before vs. close after earnings).
Looking ahead to Q1 27, -- analysts forecast an EPS of -0.42 USD, with revenue projected to reach 2.54 million USD, implying an decrease of -62.16% EPS, and increase of 743.06% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
CalciMedica, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.30
Actual
-$0.72
Surprise
+44.64%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
FAQ
What were Palatin Technologies, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2026?
For Q4 2026, Palatin Technologies, Inc. Common Stock reported EPS of -$1.11, beating estimates by 8.42%, and revenue of $301.00K, -76.16% below expectations.
How did the market react to Palatin Technologies, Inc. Common Stock's Q4 2026 earnings?
The stock price moved up 0.49%, changed from $10.22 before the earnings release to $10.27 the day after.
When is Palatin Technologies, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for Palatin Technologies, Inc. Common Stock's next earnings report?
Based on --
analysts, Palatin Technologies, Inc. Common Stock is expected to report EPS of -$0.42 and revenue of $2.54M for Q1 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.